open access
Chemotherapy of advanced non small cell lung cancer: effect on survival and symptoms affecting quality of life
open access
Abstract
Material and methods: Four regimens of chemotherapy: EP (cisplatin, vepesid), MVP (mitomycin C, vinblastin, cisplatin), PN (cisplatin,vinorelbin) and PG (cisplatin, gemcytabin) were used.
Results: Average survival time in group treated with MVP regimen was 7,8 months (median 4,3 months), PG 7,1 months (median 7,3 months), EP 10,2 months (median 7,5 months), PN 14,1 months (median 9,8 months). Differences in median survival time were not significant. Average time to progression in group treated with MVP regimen was 3,5 months (median 2,6 months), PG 5,2 months (median 5,8 months): EP 6,6 months (median 5,2 months), PN 6,7 months (median 5,6 months). Improvement in control of symptoms regarding dyspnea, pain and cough was reached in 60%, 38,7% and 60% of patients respectively. There were no significant differences between chemotherapy regimens regarding improvement in symptoms control.
Conclusions: Cisplatin + vinorelbin regimen can be recommended as standard method because of the best treatment results.
Abstract
Material and methods: Four regimens of chemotherapy: EP (cisplatin, vepesid), MVP (mitomycin C, vinblastin, cisplatin), PN (cisplatin,vinorelbin) and PG (cisplatin, gemcytabin) were used.
Results: Average survival time in group treated with MVP regimen was 7,8 months (median 4,3 months), PG 7,1 months (median 7,3 months), EP 10,2 months (median 7,5 months), PN 14,1 months (median 9,8 months). Differences in median survival time were not significant. Average time to progression in group treated with MVP regimen was 3,5 months (median 2,6 months), PG 5,2 months (median 5,8 months): EP 6,6 months (median 5,2 months), PN 6,7 months (median 5,6 months). Improvement in control of symptoms regarding dyspnea, pain and cough was reached in 60%, 38,7% and 60% of patients respectively. There were no significant differences between chemotherapy regimens regarding improvement in symptoms control.
Conclusions: Cisplatin + vinorelbin regimen can be recommended as standard method because of the best treatment results.
Keywords
non small cell lung cancer; chemotherapy; quality of life
About this articleTitle
Chemotherapy of advanced non small cell lung cancer: effect on survival and symptoms affecting quality of life
Journal
Advances in Respiratory Medicine
Issue
Article type
Research paper
Pages
343-348
Published online
2007-10-26
Bibliographic record
Pneumonol Alergol Pol 2007;75(4):343-348.
Keywords
non small cell lung cancer
chemotherapy
quality of life
Authors
Janusz Rolski
Tomasz Zemełka
Marek Jasiówka
Grzegorz Czyżewicz
Ewelina Kojs-Pasińska